Estimating the Effect of Intravenous Acetaminophen for Postoperative Pain Management on Length of Stay and Inpatient Hospital Costs by E. Eve Shaffer et al.
ORIGINAL RESEARCH
Estimating the Effect of Intravenous Acetaminophen
for Postoperative Pain Management on Length of Stay
and Inpatient Hospital Costs
E. Eve Shaffer . An Pham . Robert L. Woldman . Andrew Spiegelman .
Scott A. Strassels . George J. Wan . Thomas Zimmerman
Received: September 7, 2016 / Published online: November 9, 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
ABSTRACT
Introduction: The provision of safe, effective,
cost-efficient perioperative inpatient acute pain
management is an important concern among
clinicians and administrators within healthcare
institutions. Overreliance on opioid
monotherapy in this setting continues to
present health risks for patients and increase
healthcare costs resulting from
preventable adverse events. The goal of this
study was to model length of stay (LOS),
potential opioid-related complications, and
costs for patients reducing opioid use and
adding intravenous acetaminophen (IV APAP)
for management of postoperative pain.
Methods: Data for this study were de-identified
inpatient encounters from The Advisory Board
Company across 297 hospitals from 2012–2014,
containing 2,238,433 encounters (IV APAP used
in 12.1%). Encounters for adults C18 years of
age admitted for cardiovascular, colorectal,
general, obstetrics and gynecology,
orthopedics, or spine surgery were included.
The effects of reducing opioids and adding IV
APAP were estimated using hierarchical
statistical models. Costs were estimated by
multiplying modeled reductions in LOS or
complication rates by observed average
volumes for medium-sized facilities, and by
average cost per day or per complication (LOS:
US$2383/day; complications: derived from
observed charges).
Results: Across all surgery types, LOS showed
an average reduction of 18.5% (10.7–32.0%) for
the modeled scenario of reducing opioids by
one level (high to medium, medium to low, or
low to none) and adding IV APAP, with an
associated total LOS-related cost savings of
$4.5 M. Modeled opioid-related complication
rates showed similar improvements, averaging a
Enhanced content To view enhanced content for this
article go to http://www.medengine.com/Redeem/
BF07F0605CD22222.
E. E. Shaffer  R. L. Woldman  A. Spiegelman
The Advisory Board Company, Washington, DC,
USA
A. Pham (&)  G. J. Wan
Mallinckrodt Pharmaceuticals, Hampton, NJ, USA
e-mail: an.pham@mallinckrodt.com
S. A. Strassels




Adv Ther (2016) 33:2211–2228
DOI 10.1007/s12325-016-0438-y
reduction of 28.7% (5.4–44.0%) with associated
cost savings of $0.2 M. In aggregate, costs
decreased by an estimated $4.7 M for a
medium-sized hospital. The study design
demonstrates associations only and cannot
establish causal relationships. The cost impact
of LOS is modeled based on observed data.
Conclusions: This investigation indicates that
reducing opioid use and including IV APAP for
postoperative pain management has the
potential to decrease LOS, opioid-related
complication rates, and costs from a hospital
perspective.
Funding: Mallinckrodt Pharmaceuticals.
Keywords: Cost; Intravenous acetaminophen;
IV APAP; Length of stay; Opioid; Opioid-related
adverse drug events; ORADE; Pain;
Pharmacoeconomic; Postoperative
INTRODUCTION
The provision of safe, effective, cost-efficient
perioperative inpatient acute pain management
is an important concern among clinicians and
administrators within healthcare institutions.
Across a variety of surgeries, 20–55% of patients
report at least moderate pain and up to 75%
report severe pain during the immediate
postoperative period, for a mean duration
ranging from 1 to 8 days [1–5]. While
readmission rates after a surgical discharge
may be low, pain is a common reason for
readmission among those returning to the
hospital [6]. Additionally, untreated or
inadequately treated acute postoperative pain
can lead to chronic postsurgical pain [7].
Furthermore, adverse drug events (ADEs)
frequently are associated with postoperative
pain management regimens. In general, ADEs
have long been associated with increased
mortality, longer hospital length of stay (LOS),
and higher costs of hospitalization [8, 9].
In 2000, the United States (US) Joint
Commission on Accreditation of Healthcare
Organizations (JCAHO), now referred to as the
Joint Commission (JC), introduced pain
management standards aimed at upholding a
patient’s right to effective assessment and
treatment of pain from admission to discharge
[10]. However, the American Medical
Association (AMA) has recommended that
pain be removed as a ‘‘fifth vital sign’’ due to
concerns about opioid over-prescribing, which
critics contend could make it more difficult for
those in pain to have their pain properly
diagnosed and treated. Importantly, pain is a
key input into the JC hospital accreditation
score and the Hospital Consumer Assessment of
Healthcare Providers and Systems (HCAHPS)
CAHPS Hospital Survey, and can impact
overall hospital reimbursement by the
government.
Acute Pain Management Using Opioids
In the US, intravenous (IV) opioid agonists such
as morphine, hydromorphone, and fentanyl
have traditionally been important analgesics
in the treatment of pain in the immediate
perioperative and critical care settings [11–13].
In the first half of 2015, over 70% of surgical
inpatients and outpatients in the US received
opioid monotherapy for acute pain
management [14]. Overreliance on opioid
monotherapy in the inpatient healthcare
setting raises health risks for patients and
increases healthcare costs resulting from
preventable adverse events. Opioid
monotherapy can significantly increase a
variety of opioid-related adverse drug events
(ORADEs), most commonly nausea, vomiting,
urinary retention, fatigue, pruritus, sleep
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impairment, dizziness, sedation, somnolence,
and headache [15]. Less commonly, opioid
monotherapy has been associated with ileus
[16], respiratory depression [17], falls, and
delirium, and in some extreme cases even
death [18]. Numerous studies have
demonstrated that managing these ORADEs is
costly and they are associated with increased
LOS [19–22].
Multimodal Analgesia
As an alternative to opioid monotherapy,
multimodal analgesia (MMA) captures the
effectiveness of individual agents in optimal
dosages that maximize efficacy and attempts to
minimize side effects from one analgesic [7].
This important concept employs the theory that
agents with different mechanisms of analgesia,
such as nonopioids (acetaminophen and
nonsteroidal anti-inflammatory drugs
[NSAIDs]), opioids, local anesthetics, and
anticonvulsants, may have synergistic effects
in preventing or treating acute pain when used
in combination [7]. The efficacy of multimodal
analgesic regimens continues to improve, with
opioid analgesics increasingly taking on the role
of rescue analgesics for acute pain [23].
Multimodal analgesia has been shown to
reduce ADEs, LOS, readmissions, and costs
associated with the use of opioids in multiple
surgical populations [24, 25]. Intravenous
acetaminophen (IV APAP) has been used as a
component of an MMA strategy to help
contribute to reduced costs and improved
outcomes. Although not all studies of
perioperative use of IV APAP have
demonstrated reductions in opioid use and
LOS, recent economic impact studies have
shown reduced costs associated with IV APAP
[26, 27]. These findings are supported by a
pharmacoeconomic review of IV APAP, which
concluded the body of evidence shows the drug
has the potential to improve outcomes and
hospital efficiency [28]. Up to an estimated 7%
of patients who receive prescription opioids
following surgery end up using these
medications long-term [29–33], which can
result in tolerance, dependence, and addiction
[34]. It remains to be demonstrated whether
reductions in postoperative opioid consumption
associated with IV APAP reduce the risk of
inappropriate extended use of opioids.
The goal of the current study was to
estimate, through the use of statistical
modeling, LOS, potential opioid-related
complications, and costs for patients reducing




Data for this retrospective cohort study were
derived from de-identified hospital billing and
administrative data from the Advisory Board
Company. This comprised 2,238,433 inpatient
encounters across 297 hospitals from 1 January
2012 through 31 December 2014, with IV APAP
identified in 271,394 encounters (12.1%).
Hospitals were not segmented by size to derive
parameter estimates; however, only
medium-sized hospitals (100–399 beds) [35]
were selected to determine the number of
cases used to model cost impact.
Drug utilization (see Table 1 for a list of
opioid and non-opioid generic drug names for
which data were collected in this study) was
identified using hospital charge data for the
encounter and is subject to the typical
limitations of this approach, such as the
potential for coding errors, and charges may
not equate to amount of drug administered.
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Patient Inclusion and Exclusion Criteria
Encounters for adults C18 years of age
admitted for cardiovascular, colorectal,
general, obstetrics and gynecology (OBGYN),
orthopedics, or spine surgery based on the
encounters’ All Patient Refined
Diagnosis-Related Group (APR-DRG)
assignment (Table 2) were included. These
six surgical categories represent high-volume
procedures that were considered broadly
applicable for the purpose of analysis.
Only data from acute care facilities with
data available throughout the study period
Table 1 Opioid and non-opioid drugs used in study
Opioids NSAIDs Other non-opioids
Alfentanil Aspirin Acetaminophen, injectable
Buprenorphine Celecoxib Acetaminophen, non-injectable
Buorphanol Choline magnesium trisalicylate Alpha-2 agonists (clonidine, dexmedetomidine)
Codeine Diclofenac Gapabentinoids (gabapentin, pregabalin)
Dihydrocodeine Diﬂunisal Local anesthetics, non-topical only (bupivacaine,
lidocaine, liposomal bupivacaine, ropivacaine)Fentanyl Etodolac


















Opioids, non-steroidal anti-inﬂammatory drugs (NSAIDs) and other non-opioids used in this study are shown by generic
name. Combination product names are not shown. Only data on intravenous acetaminophen are presented in this analysis
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and having sufficient data quality to identify
drugs were included. Encounters with invalid
age, gender, or severity, without diagnoses,
without drug utilization, with mortalities or
with discharge to hospice were excluded.
LOS outliers were not removed from the
analysis.
Definition of Complications
Potential ORADEs related to respiratory,
gastrointestinal, central nervous system,
urinary, and other events were defined using
International Classification of Disease-9th
Revision-Clinical Modification (ICD-9-CM)
codes [20].
Modeling and Analytical Approach
There were two phases of modeling conducted
in the study. The first phase was to determine
parameter estimates, which describe the impact
to LOS or complication rate based on drug
utilization. The second was to employ those
parameter estimates to model a specific
treatment change and the downstream impact
of that treatment change on LOS, complication
rate, and costs. Because the data in this study
were modeled, measures of central tendency
and statistical tests of differences are not
available.
The effects of reducing opioid use and
adding IV APAP were estimated using
Table 2 APR-DRGs used in study
Category Included APR-DRGs and APR-DRG codes
Cardiovascular Other vascular procedures (173)
Percutaneous cardiovascular procedures with AMI (174)
Percutaneous cardiovascular procedures without AMI (175)
Colorectal Major small and large bowel procedures (221)
General Appendectomy (225)
Laparoscopic cholecystectomy (263)
OBGYN Uterine and adnexa procedures for non-malignancy except leiomyoma (513)
Cesarean delivery (540)
Vaginal delivery (560)
Orthopedic Hip joint replacement(301)
Knee joint replacement (302)
Hip and femur procedures for trauma except joint replacement (308)
Knee and lower leg procedures except foot (313)
Shoulder, upper arm and forearm procedures (315)
Spine Dorsal and lumbar fusion procedure except for curvature of back (304), intervertebral
disc excision and decompression (310), cervical spinal fusion and other back/neck
procedures excluding disc excision and decompression (321)
All Patients Reﬁned Diagnosis Related Groups (APR-DRGs) by category and code used in this study are shown
AMI Acute myocardial infarction
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hierarchical statistical models in Statistical
Analysis Software (SAS) 9.4. Independent
variables analyzed were opioid use [none (no
use)/low (1–3 estimated doses for 1 or 2 days)/
medium (4–8 estimated doses or 3 days’ use)/
high (more than 8 estimated doses or greater
than 3 days’ use)], non-opioid use (none/low/
medium/high) and IV APAP use (none/used).
Covariates were age, gender, Elixhauser
comorbidity index, APR-DRG severity level,
and admission type.
Stratified cluster sampling was conducted
within each APR-DRG (sample size *15,000,
with sample weights used to adjust for percent
of each hospital encounter selected), and
multiple replication studies were conducted to
ensure robust results. Statistical modeling was
used to determine parameter estimates for LOS
and complications. Observed average LOS plus
cost and charge data were used along with the
parameter estimates to develop per-episode and
per-facility cost impact estimates.
Cost impact estimates were generated by
multiplying modeled reductions in LOS or
complication rates by observed average
volumes [facilities designated American
Hospital Association (AHA) 100–399 beds], and
by average cost per day of LOS or per
complication [LOS: US$2383/day (national
benchmark from the Healthcare Cost and
Utilization Project, HCUP, 2013),
complications: derived from observed charges]
(Tables 3, 4).
Details of the Regression Modeling
Hierarchical regressions were performed on
random samples of n = 15,000 from the full
sample (n = 2,238,443). Specifically, separate
regressions were performed for each APR-DRG
(17 total) and each of those regressions had a
random sample of n = 15,000 from the given
APR-DRG. These regressions were replicated
with additional n = 15,000 samples to verify
robustness of results and mitigate concerns
about multiple comparisons. The levels used
in hierarchical modeling were ‘‘facility’’ and
‘‘attending physician,’’ with individual
hospitalizations within those two levels.
The first outcome of interest was LOS in
days, which was modeled using hierarchical
linear regression on its natural logarithm. The
second outcome of interest was complications,
which were grouped into six binary variables
based on the ICD-9-coded categories
(respiratory, urinary, central nervous system,
GI, general, and related) and modeled each
using hierarchical logistic regression.
As predictors, the following were included:
Opioids (ordinal, 0/1/2/3), non-opioids
(ordinal, 0/1/2/3), IV APAP (binary, 0/1),
patient gender, Elixhauser comorbidity score
(continuous, 1–15, although it can theoretically
be as high as 31), patient age, APR-DRG severity
level (ordinal, 1–4), ICD-9-coded complications
(binary, 0/1), admission type (categorical:
‘‘emergency,’’ ‘‘urgent,’’ ‘‘elective,’’ ‘‘other’’),
and interactions between Elixhauser and each
of (age, admission type, APR-DRG severity, and
complications). Note that complications were
predictors only in the LOS outcome models,
and not in the complications outcome models.
This article does not contain any new studies
with human or animal subjects performed by
any of the authors.
RESULTS
Overall
To put the impact of the LOS and complication
rate reductions in context, the potential
impact was modeled for a hypothetical
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medium-sized hospital. In aggregate, including
both LOS- and complications-related
reductions, annual costs for a medium-sized
hospital were modeled to decrease by an
estimated $4.7 M by reducing opioid use and
adding IV APAP for postoperative pain
management in patients undergoing
cardiovascular, colorectal, general, OBGYN,
orthopedic, or spine surgery. Cost savings
were driven by reductions in LOS and
complication rates; the cost of IV APAP was
not included in the analyses. A subgroup
analysis was performed on outlier LOS, which
demonstrated no overall impact on results.
Table 3 Sample calculations: LOS results (reducing one level of opioid use and adding IV APAP)
Variables
CNT = Observed average annual number of cases for medium-sized facilities (AHA, 100–399 beds)
cCNT = Observed average annual number of cases for medium-sized facilities (AHA, 100–399 beds) for all APR-DRG
in the category
ALOS = Observed average length of stay in days for the APR-DRG
cALOS = Calculated average length of stay in days for the category
ALOSop = Calculated average length of stay for reducing one level of Opioid use
ALOSiv = Calculated average length of stay for reducing one level of Opioid use and adding IV APAP
cALOSiv = Calculated average length of stay for reducing one level of opioid use and adding IV APAP for the category
Bop = Opioid regression parameter
Biv = IV APAP regression parameter
Cost per day of LOS (2013 HCUP): $2383
APR-DRG level
ALOSop = ALOS - (Bop 9 ALOS) and ALOSiv = ALOSop ? (Biv 9 ALOSop)
Calculated LOS reduction = ALOS - ALOSiv
% change of LOS reduction = (ALOS - ALOSiv)/ALOS
Calculated per episode LOS cost savings = (ALOS - ALOSiv) 9 $2383
Calculated annual LOS cost savings (average medium-sized facility) = (ALOS - ALOSiv) 9 $2383 9 CNT
Category level
cCNT = S(CNT) and cALOS = S(ALOS 9 CNT)/cCNT
ALOSop = ALOS - (Bop 9 ALOS) and ALOSiv = ALOSop ? (Biv 9 ALOSop)
cALOSiv = S(ALOSiv 9 CNT)/cCNT
Calculated LOS reduction for the category, rounded = cALOS - cALOSiv
% change of LOS reduction for the category, rounded = (cALOS - cALOSvi)/cALOS
Calculated annual LOS cost savings (average medium-sized facility),
rounded = (cALOS - cALOSiv) 9 $2383 9 cCNT
Sample calculation methods used to model length of stay (LOS) results by reducing one level of opioid use and adding
intravenous acetaminophen (IV APAP) are shown
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Table 4 Sample calculations: complications results (reducing one level of opioid use and adding IV APAP)
Variables
CNT = Observed average annual number of cases for medium-sized facilities (AHA, 100–399 beds)
cCNT = Observed average annual number of cases for medium-sized facilities (AHA, 100–399 beds) for all APR-DRG
in the category
ACR = Observed average complication rate
cACR = Calculated average complication rate for the category
ACRop = Calculated average complication rate for reducing one level of Opioid use
ACRiv = Calculated average complication rate for reducing one level of Opioid use and adding IV APAP
cACRiv = Calculated average complication rate for reducing one level of Opioid use and adding IV APAP for the
category
Bop = Opioid regression parameter Biv = IV APAP regression parameter
CCR = Typical cost-to-charge-ratio = 0.2
CPC = Observed average charge increase per complication
cCPC = Observed average charge increase per complication for the category
CST = Charge-derived cost increase per complication c
CST = Charge-derived cost increase per complication for the category
APR-DRG level
ACRop = ACR - (Bop 9 ACR) and ACRiv = ACRop ? (Biv 9 ACRop)
Calculated complication rate reduction = ACR - ACRiv
% change of complication rate reduction = (ACR - ACRiv)/ACR
CST = CPC 9 CCR
Reduction in complications = (ACR - ACRiv) 9 CNT
Calculated annual complication reduction cost savings (average medium-sized
facility) = (ACR - ACRiv) 9 CNT 9 CST
Category level
cCNT = S(CNT) and cACR = S(ACR 9 CNT)/cCNT
ACRop = ACR - (Bop 9 ACR) and ACRiv = ACRop ? (Biv 9 ACRop)
cACRiv = S(ACRiv 9 CNT)/cCNT
Calculated complication rate reduction = cACR - cACRiv
% change of complication rate reduction = (cACR - cACRiv)/cACR
CST = CPC 9 CCR
cCPC = S(CPC 9 CNT)/cCNT
cCST = S(CST 9 CNT)/cCNT
Reduction in complications = (cACR - cACRiv) 9 cCNT
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Length of Stay
Across all surgery types, LOS showed an average
of 18.5%/1898.85 cumulative total days
reduction at the category level (categories
ranging from 10.7%/456.17 total days to
32.0%/161.12 total days) for the modeled
scenario of reducing opioid use by one level
(high to medium, medium to low, or low to
none) and replacing it with IV APAP, with an
associated total LOS-related annual cost savings
of $4.5 M (Table 5). For example, the calculated
annual impact for a medium-sized facility
(admissions 9 LOS reductions 9 HCUP 2013
$2383 cost per day of LOS) for the
cardiovascular category overall (see first row in
Table 5) is 276 9 1.01 9 2383 = $660,000
(rounded). Of note, the absence of P values
and confidence intervals in Table 5 and Table 6
was due to derivation of cost savings estimates
from a mix of nationally published reference
costs and admission volumes, in addition to the
parameter estimates from analysis of the
observed data.
At the category level, general surgery showed
the largest percentage reduction in LOS
(32.0%/total 161.12 days), while orthopedics,
with much larger average case volume, showed
the largest LOS-related cost reduction
($1,340,000). OBGYN showed the lowest
percentage reduction in LOS (10.7%/456.17
total days) (Table 5).
At the APR-DRG level, knee and lower leg
procedures showed the largest percentage
reduction in LOS (39.0%/84.00 total days),
closely followed by dorsal and lumbar fusion
(34.5%/137.16 total days) and laparoscopic
cholecystectomy (34.3%/123.48 total days),
while cesarean delivery, with much larger
average case volume, showed the largest
LOS-related cost reduction ($600,000), despite
having a low percentage reduction in LOS
(13.5%/253.44 total days). Vaginal delivery
showed the lowest percentage reduction in
LOS (7.5%/167.62 total days), while uterine
and adnexa procedures, with lower average
case volume, showed the smallest LOS-related
cost reduction ($80,000) (Table 5).
Potential Opioid-Related Complications
Reducing opioid use and adding IV APAP
resulted in a reduction in the modeled opioid
complication rate by an average of 28.7% (range
5.4–44.0%), with associated
complications-related annual cost savings of
$0.2 M (Table 6).
At the category level, spine showed the
largest percentage reduction in complications
(44.0%) and the largest complications
rate-related cost reduction ($70,000). The
cardiovascular category showed the smallest
percentage reduction in complications (5.4%)
and the smallest complications-related cost
savings ($10,000), along with the OBGYN
category (Table 6).
At the APR-DRG level, dorsal and lumbar
spinal fusion showed the largest percentage
reduction in complications (46.8%), while
bowel procedures showed the largest
Table 4 continued
Calculated annual complication reduction cost savings (average medium-sized
facility) = (cACR - cACRiv) 9 cCNT 9 cCST
Sample calculation methods used to model complication results by reducing one level of opioid use and adding intravenous
acetaminophen (IV APAP) are shown
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complications-related cost reduction ($60,000).
Percutaneous cardiovascular procedures
without acute myocardial infarction (AMI)
showed the lowest percentage reduction in
complication rate (-43.5%), as well as the
lowest complications-related cost reduction
($20,000)—indicating that opioid reduction
was modeled to have an adverse impact on
complication rates for procedures in this
APR-DRG. However, for the other 16
APR-DRGs, opioid reduction was modeled to
have a positive impact on reducing
complication rates for those procedures
(Table 6).
DISCUSSION
While opioid therapy is a fundamental
component of postoperative pain
management, the risk of ADEs and negative
patient outcomes pose significant safety
concerns [36]. Increasingly, a multimodal
approach to pain management is being used as
a way to decrease postoperative opioid reliance
but still provide optimal pain control [37].
Because of reduced opioid doses used, this new
approach to pain management may decrease
the risk of ORADEs [24, 38] and associated
health care costs [25, 38]. Recent pain
guidelines for critically ill patients suggest this
approach to avoid ADEs [12]. Since hospitals
and outpatient clinics strive to provide care in
an efficient and cost-effective manner to survive
in the current budget-conscious healthcare
climate, a major issue is providing balanced
pain management while using the lowest
effective dose of opioids. In particular,
HCAHPS scores are tied to reimbursement, and
two questions relate to pain management [39].
Prior studies have demonstrated
postoperative use of IV APAP reduces opioid
consumption. In the pivotal US study of IV
APAP for acute pain management, IV APAP was
associated with a 46% reduction over the first
6 h and 33% reduction (vs. placebo) in total
morphine consumption in the first 24 h
following surgery [40]. Other randomized
controlled trials (RCTs) have shown reductions
in opioid consumption up to 78% [e.g., 41–45].
Taken together, results from prior studies
[46–48] and the current analysis suggest a
positive impact on overall hospital costs
associated with reducing opioid consumption
and adding IV APAP. Accordingly, IV APAP may
be recommended as a standard of care in MMA
regimens for postoperative pain management to
reduce reliance on opioid monotherapy.
In RCTs, postoperative use of IV APAP has
been associated with a shorter average LOS
(0.4–1.5 days) relative to placebo or active
controls [41, 45, 49]. In addition, a
retrospective cohort study of case-matched
patients who underwent total hip or knee
replacement surgery [38], IV APAP used as part
of an MMA strategy was associated with
improved clinical outcomes in terms of fewer
overall adverse events, shortened LOS, and
reduced total hospital resources. A total of
22,146 cases and controls were similar in
terms of age, race, sex, marital status,
insurance status, and preoperative
comorbidities. Overall adverse events were
significantly lower with IV APAP (24.3%) than
with controls (26.3%, P\0.001), numerically
less frequent in all subgroups, and significantly
less frequent for renal, infectious, and
miscellaneous adverse events (all P\0.05).
Also, IV APAP was associated with a shorter
LOS, with 1 out of 11 patients discharged 1 day
earlier (P\0.001) and lower average hospital
costs: $16,381 for cases compared with $16,927
for controls (P\0.001). Cost savings estimated
by structural equation modeling of $547 per
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patient were due to $325 from direct effects and
$222 from indirect effects, the latter mediated
through adverse events and reduced LOS.
In the current study, the largest percentage
reduction in LOS and opioid-related
complications, seen in the spine category, may
represent a greater benefit of adding IV APAP in
more painful procedures. Specifically, spine
surgery and other painful procedures generally
require higher doses and/or more frequent
administration of pain medications, with
opioids used predominantly. Reducing the use
of opioids in these patients by using IV APAP as
part of an MMA strategy [50, 51] can reduce
ORADE incidence and LOS [47, 52] while also
reducing hospitalization costs [47].
In summary, the purpose of this study was to
model the impact of reducing postoperative
opioid use by implementing an MMA approach
utilizing IV APAP. This investigation indicates
that reducing opioid use and including IV APAP
during treatment can contribute to decreased
LOS, opioid-related complication rates, and costs
from a hospital perspective. A subsequent
sensitivity analysis restricting the data to the
24-h postoperative period was utilized to serve as
an estimate of ‘‘perioperative’’ use on outcome
measures. Results from this sensitivity analysis
were similar to the current analysis.
Limitations of the Study
Although the authors consider the results of the
current study to be valid, certain
methodological procedures were not feasible
to perform that would have enhanced rigor.
Specifically, propensity scores or any other kind
of pre-analysis matching data treatments were
not used. In addition, study constraints
precluded matching.
Opioid and non-opioid drug doses were
categorized according to charge data, which
has limited precision in regards to
quantity/doses of drug a patient received.
Therefore, ordinal bucketed categories were
used instead of continuous measures.
Estimated dosing was based on quantities
charged, which is not a consistent
representation of actual dosing. Out-of-range
quantities were adjusted based on assumptions
of use of mg/mL as charge quantities rather
than dose quantity.
Use of IV APAP was coded as a binary yes/no.
Due to study constraints, as with opioid and
non-opioid cases, a finer measure could not be
used.
As listed in the regression details, some
interactions were included whereas others were
not. Optimally, the many dozens of different
kinds of interactions between all our variables
would have been examined, but, due to the large
number of models involved in this study (17
APR-DRGs across 2 outcomes equals 34 models
of interest), it was unfeasible to produce highly
customized models for each case.
The limitations noted here raise the question
whether all of the different modeling decisions
made put the analysis at risk of implicit
multiple comparisons problems [53, 54]. While
the data were not modeled in all of the
variations desired, an attempt was made to
mitigate the multiple concern by replicating
regression results with new samples, as
mentioned above. The replications performed
also confirmed the findings of this analysis.
Future Research Considerations
Although the current study collected data on
non-opioid pain medications in addition to IV
APAP, analysis of these data was beyond the
scope of the current study and may warrant
future analysis and reporting. Additional work
to better understand the impact of opioid
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reduction on percutaneous cardiovascular
procedures without AMI may be of interest.
Also, analysis of specific MMA approaches to
identify the APR-DRGs for which they appear to
provide the most benefit with respect to
decreased LOS, opioid-related complication
rates, and overall hospital costs may be
warranted.
CONCLUSIONS
Prevention of ORADES rather than treatment of
ADEs is a more effective strategy for hospitals,
given the large economic burden and negative
impact on patient outcomes associated with
these events. A multimodal approach is a
growing strategy to minimize the frequency of
ORADEs as well as associated costs.
This investigation indicates that reducing
opioid use and including IV APAP for
postoperative pain management has the
potential to decrease LOS, opioid-related
complication rates, and costs from a hospital
perspective.
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